We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

QT Variability Pre and Post Cardioversion (DCCV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885391
Recruitment Status : Completed
First Posted : April 22, 2009
Last Update Posted : December 11, 2014
Information provided by (Responsible Party):

April 20, 2009
April 22, 2009
December 11, 2014
January 2007
March 2012   (Final data collection date for primary outcome measure)
QT variability before and after direct current cardioversion [ Time Frame: 1.5 ]
Not Provided
Complete list of historical versions of study NCT00885391 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
QT Variability Pre and Post Cardioversion
QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation
The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.
Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Blood sample
Probability Sample
Cardiology Clinic Hospital inpatient
Atrial Fibrillation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 21 years of age
  • Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

  • Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
  • Undergoing DC-Cardioversion for post-cardiac surgery
  • Dual chamber pacemakers
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R01HL085690-01A2 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Dawood Darbar, Vanderbilt University
Vanderbilt University
  • National Institutes of Health (NIH)
  • Wake Forest University Health Sciences
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C. Vanderbilt University Medical Center
Vanderbilt University
December 2014